Oral Inhaled Cromolyn for Mild-to-Moderate Amyotrophic Lateral Sclerosis: A Randomized, Open Label Phase 2a Study.
Brazier, D.; Stemmer, S. M.; Garofano, W.; Gupta, A.; Conti, P. S.; Elmaleh, D. R.
Show abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor neuron system for which there is currently no effective treatment. This study aims to evaluate the safety and efficacy of two doses of oral inhaled cromolyn in mild to moderate ALS over 12 weeks. The primary efficacy parameter is the plasma neuroinflammatory biomarkers. The exploratory parameters are the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), forced vital capacity (FVC%), and peak inspiratory flow rate (PIFR). The study recruits 12 participants. A favorable decrease in proinflammatory plasma biomarkers is observed in 12 of the 18 biomarkers following 12-week treatment. Additionally, exploratory efficacy assessments demonstrated highly favorable trends: the ALSFRS-R score declined by -0.77 points per month (-2.6 points over 12 weeks), markedly better than the typical decline of around -1 point per month seen in ALS patients. The decline in FVC was equally impressive at just -0.51% per month (-1.53% over 12 weeks), significantly lower than the usual 3-5% monthly decline. Both doses are found to be safe and well-tolerated. Despite fewer participants, this study provides preliminary evidence supporting oral inhaled cromolyns safety and potential efficacy in ALS treatment.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A low molecular weight dextran sulphate, ILB(R), for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial 96%
- Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: a potential new treatment route for amyotrophic lateral sclerosis 93%
- Masitinib Limits Neuronal Damage, as Measured by Serum Neurofilament Light Chain Concentration, in a Model of Neuroimmune-Driven Neurodegenerative Disease 92%
Similar papers in this journal
- Factors Impacting Quality of Life in Multiple System Atrophy 92%
- A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data 91%
- Metabolic and muscle-derived serum biomarkers define CHCHD10-linked late-onset spinal muscular atrophy 90%
Similar papers in this journal
Similar papers in this journal
- Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis 95%
- What is the value of community oximetry monitoring in people with SARS-CoV-2? – A prospective, open-label clinical study 89%
- EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCE 88%
Similar papers in this journal
- Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial 94%
- Assessment of the Reliability, Responsiveness, and Meaningfulness of the Scale for the Assessment and Rating of Ataxia (SARA) for Lysosomal Storage Disorders 94%
- Improving prediction models of amyotrophic lateral sclerosis (ALS) using polygenic, pre-existing conditions, and survey-based risk scores in the UK Biobank 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.